4.9 million UK adults have used GLP-1 drugs, study finds

The study

Published in the first quarter of 2026, this population-level study surveyed UK adults on GLP-1 use and interest. The headline figure — 4.9 million users — represents adults in Great Britain who had used a GLP-1 receptor agonist for weight loss in the recent period. The study also found that 22% of UK adults would use a GLP-1 weight-loss drug if available on prescription through the NHS.

The research was conducted December 2024 with a sample of 2,161 UK adults, making it one of the most current estimates of GLP-1 adoption in the UK market. The findings put hard numbers on what the clinic industry already knows: demand is vast and growing.

Why it matters for regulation

This scale explains the regulatory intensity. The ASA's enforcement report found ~900 POM ad violations in a single sweep — that's the demand side driving aggressive marketing. The GPhC classified weight-management medicines as "high risk" and found widespread weaknesses in pharmacy safeguards. The MHRA is actively enforcing against unlicensed products. None of this regulatory activity is happening in a vacuum. 4.9 million users means 4.9 million potential patients interacting with online pharmacies, aesthetic clinics, and weight-loss providers — and each interaction carries regulatory risk.

The sheer market size also explains why the ASA, GPhC, and MHRA are coordinating enforcement. This is not a niche issue. It is the largest consumer health market to hit UK private healthcare in decades, and the regulators are responding in real time.

Key takeaway

For clinic owners and compliance teams: the regulatory pressure on GLP-1 advertising and prescribing is not temporary. It is a structural response to a structural market shift. Compliance frameworks for weight-loss medicine marketing and prescribing need to be built for the long term, not treated as a temporary hassle.